Repligen Corporation (RGEN) is a publicly traded company in the Healthcare — Medical - Instruments & Supplies industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing.
Is Repligen Corporation stock overvalued or undervalued in 2026?
As of October 2, 2026, Repligen Corporation (RGEN) trades at 256× earnings (P/E), against a median of 27.5× across the 157 pharma companies above $2bn in Kaplio's universe. Kaplio's verdict: expensive. At its sector median (27.5×) $20 (-89 %).
Kaplio overview: Repligen Corporation
Market cap $11B · 52 weeks $103 – $195 (3 % below the high) · P/E 256× · 2027 expected P/E 71.9× · Dividend none · Next earnings November 3, 2026 · expected EPS $0.46 · Price as of Oct 2 · accounts published Jul 28.
- Valuation: P/E 256.1× (expensive).
- Business: ROIC 2 % (weak).
- Balance sheet: Net debt/EBITDA 0.8× (solid).
- Earnings: 7 of 8 (on track).
What would it be worth at its usual multiples?
At its sector median (27.5×) $20 (-89 %). Implied price from applying the reference multiples to today's earnings (or book value, or FFO) per share. Not a fair value: it is where the stock would trade at its usual multiples.
What matters in pharma: 2 of 7 pass
- R&D / Revenue 7.3 %, fails.
- 5y EPS growth −5.3 %, fails.
- Gross margin 47.1 %, fails.
- ROIC 1.8 %, fails.
- P/E vs own 10y history 256.1×, fails.
- FCF / Net Income 192.0 %, passes.
- Net debt / EBITDA 0.8×, passes.
Against its peers (reference peers) — Repligen Corporation: P/E 256×; EV/EBITDA 88.5×; ROIC 1.8 %; $10.7B. Avantor, Inc. (P/E —; EV/EBITDA 81.8×; ROIC -2.4 %; $10.3B), Baxter International Inc. (P/E —; EV/EBITDA 26.2×; ROIC -1.6 %; $12.1B), AptarGroup, Inc. (P/E 21.4×; EV/EBITDA 11.0×; ROIC 9.2 %; $7.7B).
Profitability
| Return on Equity | 1.98% |
| Return on Invested Capital | 1.83% |
| Return on Assets | 1.41% |
| Gross Margin | 51.05% |
| Operating Margin | 8.32% |
| Net Margin | 5.29% |
Financial Health
| Debt / Equity | 0.33 |
| Current Ratio | 9.05 |
| Piotroski F-Score | 7 |
| Altman Z-Score | 7.49 |
Price Performance
| 1 month | +13.07% |
| 3 months | +37.91% |
| Year-to-date | +15.65% |
| 1 year | +26.25% |
| 3 years | +23.37% |
| 5 years | -30.37% |
Related companies: ATR · AVTR · BAX · BIO · CRL · DVA · GMED
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of RGEN: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks